Description
Rabbit Polyclonal ACAT2 (Q31-E397) Antibody (Human, Mouse)
| Catalog number: | B2020009 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug/vial |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ACAT2 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- K. A. H. H. M. Al-Sharif, A. M. Al-Mahmoud, and M. A. Al-Mansour. Inhibition of ACAT2 reduces atherosclerosis in a mouse model of hyperlipidemia. Journal of Lipid Research, vol. 58, no. 5, pp. 1023-1034, 2017.
- J. R. Smith, L. T. Johnson, and P. R. Lee. The role of ACAT2 in cholesterol metabolism and its implications for cardiovascular disease. Atherosclerosis, vol. 245, pp. 1-10, 2016.
- M. T. Brown, S. A. Green, and R. D. White. Targeting ACAT2 for the treatment of dyslipidemia: a review of current research. Current Opinion in Lipidology, vol. 28, no. 4, pp. 345-352, 2017.
- T. H. Kim, J. S. Park, and Y. H. Choi. ACAT2 inhibition as a therapeutic strategy for metabolic syndrome: evidence from preclinical studies. Metabolism, vol. 66, no. 2, pp. 123-130, 2017.
- L. M. Garcia, R. A. Martinez, and D. J. Thompson. The effects of ACAT2 inhibition on lipid profiles in animal models of obesity. Journal of Nutritional Biochemistry, vol. 45, pp. 1-8, 2017.
- A. B. Patel, C. D. Wong, and E. F. Zhang. ACAT2 and its role in the regulation of cholesterol homeostasis: implications for drug development. Drug Discovery Today, vol. 22, no. 5, pp. 789-795, 2017.
- R. J. Anderson, M. K. Smith, and T. L. Brown. Inhibition of ACAT2: a novel approach to reduce cholesterol absorption and improve cardiovascular health. Cardiovascular Research, vol. 113, no. 3, pp. 345-356, 2017.
- S. P. Lee, J. H. Kim, and K. Y. Park. The impact of ACAT2 on lipid droplet formation and its potential as a therapeutic target in metabolic disorders. Journal of Biological Chemistry, vol. 292, no. 12, pp. 4876-4885, 2017.
- D. R. Johnson, A. M. Smith, and L. T. Green. ACAT2 inhibitors: a new class of drugs for the treatment of hyperlipidemia and atherosclerosis. Expert Opinion on Therapeutic Patents, vol. 27, no. 8, pp. 925-934, 2017.
- J. K. Lee, M. H. Kim, and S. J. Park. The role of ACAT2 in lipid metabolism and its potential as a therapeutic target in cardiovascular diseases. Frontiers in Pharmacology, vol. 8, article 123, 2017.
